Appointment of Non–Executive Director
16. Mai 2022 07:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that Mr Lefei Sun has been appointed as a...
HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
02. Mai 2022 06:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food...
Update on Status under Holding Foreign Companies Accountable Act
31. März 2022 00:00 ET
|
HUTCHMED (China) Limited
HONG KONG, and SHANGHAI, China and FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its...
Update on Status under Holding Foreign Companies Accountable Act
11. März 2022 04:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an...
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
06. März 2022 23:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from...
HUTCHMED announces retirement of CEO and appointment of new CEO
03. März 2022 07:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces: (a) the retirement of Mr....
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
03. März 2022 07:00 ET
|
HUTCHMED (China) Limited
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five...
HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
01. März 2022 03:30 ET
|
HUTCHMED (China) Limited
HONG KONG and FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received approval to market...
HUTCHMED to Announce 2021 Final Results
07. Februar 2022 03:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the...
HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China
04. Februar 2022 04:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase...